spacer
home > ebr > summer 2017 > hidden treasures
PUBLICATIONS
European Biopharmaceutical Review

Hidden Treasures

Nowadays, both the EMA and FDA want to see treatments based on solid evidence, but how can we document this? For many different diseases, therapeutic effects seem to be poorly defined and challenging to monitor. Fighting a symptom, such as lowering the body’s temperature during a fever, does not count. Truly desirable effects that should be assessed or monitored would include killing bad bacteria in case of an infection, thus lowering the body’s bacterial load.

Usual Matrix Used

Each individual biomarker is part of one or more of seven categories, as defined by the FDA and National Institutes of Health Working Group, including diagnostic, monitoring, prognostic and safety. Biomarkers are endogenous substances, usually easiest to determine in blood plasma, saliva or urine. These bodily fluids are not difficult to obtain and derived from or connected to the bloodstream, which nourishes all organs and is also in contact with the central nervous system and the cerebrospinal fluid. This blood-brain barrier protects our control centre from the detrimental influences of a great number of large molecular substances, which are not able to cross it.

Historically, many may first think of protein biomarkers. Proteins may indeed be closer to the body’s reaction to a disease than small molecules. However, detecting these specific proteins in the blood is not always easy. We have many thousands of proteins in the body which consist of amino acids, and the sequence of the connected amino acids is responsible for the function of the protein.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Professor Hermann Mascher, founder and Bioanalytical Consultant at pharm-analyt Labor, has more than 100 publications in peer-reviewed journals, including two books by Wiley-VCH. He is also the inventor of three patents for biomarkers in the area of rare lysosomal storage diseases: Gaucher, NPC and metachromatic leukodystrophy.
spacer
Professor Hermann Mascher
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Arquer Diagnostics Appoints Nadia Whittley as CEO


More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

BioProduction Congress 2017

17-18 October 2017, Convention Centre Dublin, Ireland

Save the date to attend the 16thAnnual BioProduction Congress; Europe’s leading and largest event for a comprehensive update on all aspects of large scale mammalian and microbial biological manufacturing.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement